A randomized, double-blind, placebo-controlled, cross-over trial to investigate the effect of GSK189075 [remogliflozin etabonate] on cardiac repolarization as compared to placebo and a single dose of moxifloxacin in healthy adult subjects.
Latest Information Update: 26 Jun 2023
At a glance
- Drugs Remogliflozin etabonate (Primary) ; Moxifloxacin
- Indications Bacterial infections; Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 19 Jun 2008 Status changed from recruiting to completed according to clinicaltrials.gov.
- 02 Nov 2007 Status changed from initiated to recruiting.
- 02 Oct 2007 New trial record.